Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines

Martina Zimmermann, Fabrizio Gardoni, Elena Marcello, Francesca Colciaghi, Barbara Borroni, Alessandro Padovani, Flaminio Cattabeni, Monica Di Luca

Research output: Contribution to journalArticle

Abstract

Acetylcholinesterase inhibitors (AChEIs) are the only currently available drugs for treating Alzheimer's Disease (AD). Some authors have suggested a function of AChEIs not only in the induction of AChE overproduction and alternative splicing shifts but also a possible role of these drugs in amyloid metabolism beyond their well-known symptomatic effect. Here, we investigate the mechanisms of action of the AChEI donepezil on APP (amyloid precursor protein) metabolism and on the activity/trafficking of the alpha-secretase candidate ADAM 10, in differentiated human neuroblastoma cells (SH-SY5Y). In these cells, the activity of AChE is significantly decreased after 2 h of donepezil treatment. Further, SH-SY5Y cells released significantly more sAPPα into the medium, whereas total APP levels in cell lysates were unchanged. Interestingly, treated cells showed increased ADAM 10 levels in membrane compartments. This effect was prevented by pretreatment with tunicamycin or brefeldin, suggesting that donepezil affects trafficking and/or maturation of ADAM 10; additionally, this pretreatment significantly decreased sAPPα levels. Pre-incubation with atropine decreased release of sAPPα significantly but did not revert ADAM 10 activity to control levels further suggesting that donepezil acts not solely through a purely receptor mediated pathway. These findings indicate that donepezil exerts multiple mechanisms involving processing and trafficking of key proteins involved in AD pathogenesis.

Original languageEnglish
Pages (from-to)1489-1499
Number of pages11
JournalJournal of Neurochemistry
Volume90
Issue number6
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Cholinesterase Inhibitors
Neuroblastoma
Cells
Cell Line
Amyloid beta-Protein Precursor
Metabolism
Alzheimer Disease
Tunicamycin
Amyloid Precursor Protein Secretases
Level control
Alternative Splicing
Protein Transport
Atropine
Amyloid
Pharmaceutical Preparations
donepezil
Membranes
Processing
Proteins

Keywords

  • Acetylcholinesterase
  • ADAM 10
  • Alzheimer's disease
  • Donepezil
  • Neuroblastoma
  • Trafficking

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Zimmermann, M., Gardoni, F., Marcello, E., Colciaghi, F., Borroni, B., Padovani, A., ... Di Luca, M. (2004). Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. Journal of Neurochemistry, 90(6), 1489-1499. https://doi.org/10.1111/j.1471-4159.2004.02680.x

Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. / Zimmermann, Martina; Gardoni, Fabrizio; Marcello, Elena; Colciaghi, Francesca; Borroni, Barbara; Padovani, Alessandro; Cattabeni, Flaminio; Di Luca, Monica.

In: Journal of Neurochemistry, Vol. 90, No. 6, 09.2004, p. 1489-1499.

Research output: Contribution to journalArticle

Zimmermann, M, Gardoni, F, Marcello, E, Colciaghi, F, Borroni, B, Padovani, A, Cattabeni, F & Di Luca, M 2004, 'Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines', Journal of Neurochemistry, vol. 90, no. 6, pp. 1489-1499. https://doi.org/10.1111/j.1471-4159.2004.02680.x
Zimmermann, Martina ; Gardoni, Fabrizio ; Marcello, Elena ; Colciaghi, Francesca ; Borroni, Barbara ; Padovani, Alessandro ; Cattabeni, Flaminio ; Di Luca, Monica. / Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. In: Journal of Neurochemistry. 2004 ; Vol. 90, No. 6. pp. 1489-1499.
@article{9f662ba08b4f4d258c6e5402cd8c4089,
title = "Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines",
abstract = "Acetylcholinesterase inhibitors (AChEIs) are the only currently available drugs for treating Alzheimer's Disease (AD). Some authors have suggested a function of AChEIs not only in the induction of AChE overproduction and alternative splicing shifts but also a possible role of these drugs in amyloid metabolism beyond their well-known symptomatic effect. Here, we investigate the mechanisms of action of the AChEI donepezil on APP (amyloid precursor protein) metabolism and on the activity/trafficking of the alpha-secretase candidate ADAM 10, in differentiated human neuroblastoma cells (SH-SY5Y). In these cells, the activity of AChE is significantly decreased after 2 h of donepezil treatment. Further, SH-SY5Y cells released significantly more sAPPα into the medium, whereas total APP levels in cell lysates were unchanged. Interestingly, treated cells showed increased ADAM 10 levels in membrane compartments. This effect was prevented by pretreatment with tunicamycin or brefeldin, suggesting that donepezil affects trafficking and/or maturation of ADAM 10; additionally, this pretreatment significantly decreased sAPPα levels. Pre-incubation with atropine decreased release of sAPPα significantly but did not revert ADAM 10 activity to control levels further suggesting that donepezil acts not solely through a purely receptor mediated pathway. These findings indicate that donepezil exerts multiple mechanisms involving processing and trafficking of key proteins involved in AD pathogenesis.",
keywords = "Acetylcholinesterase, ADAM 10, Alzheimer's disease, Donepezil, Neuroblastoma, Trafficking",
author = "Martina Zimmermann and Fabrizio Gardoni and Elena Marcello and Francesca Colciaghi and Barbara Borroni and Alessandro Padovani and Flaminio Cattabeni and {Di Luca}, Monica",
year = "2004",
month = "9",
doi = "10.1111/j.1471-4159.2004.02680.x",
language = "English",
volume = "90",
pages = "1489--1499",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines

AU - Zimmermann, Martina

AU - Gardoni, Fabrizio

AU - Marcello, Elena

AU - Colciaghi, Francesca

AU - Borroni, Barbara

AU - Padovani, Alessandro

AU - Cattabeni, Flaminio

AU - Di Luca, Monica

PY - 2004/9

Y1 - 2004/9

N2 - Acetylcholinesterase inhibitors (AChEIs) are the only currently available drugs for treating Alzheimer's Disease (AD). Some authors have suggested a function of AChEIs not only in the induction of AChE overproduction and alternative splicing shifts but also a possible role of these drugs in amyloid metabolism beyond their well-known symptomatic effect. Here, we investigate the mechanisms of action of the AChEI donepezil on APP (amyloid precursor protein) metabolism and on the activity/trafficking of the alpha-secretase candidate ADAM 10, in differentiated human neuroblastoma cells (SH-SY5Y). In these cells, the activity of AChE is significantly decreased after 2 h of donepezil treatment. Further, SH-SY5Y cells released significantly more sAPPα into the medium, whereas total APP levels in cell lysates were unchanged. Interestingly, treated cells showed increased ADAM 10 levels in membrane compartments. This effect was prevented by pretreatment with tunicamycin or brefeldin, suggesting that donepezil affects trafficking and/or maturation of ADAM 10; additionally, this pretreatment significantly decreased sAPPα levels. Pre-incubation with atropine decreased release of sAPPα significantly but did not revert ADAM 10 activity to control levels further suggesting that donepezil acts not solely through a purely receptor mediated pathway. These findings indicate that donepezil exerts multiple mechanisms involving processing and trafficking of key proteins involved in AD pathogenesis.

AB - Acetylcholinesterase inhibitors (AChEIs) are the only currently available drugs for treating Alzheimer's Disease (AD). Some authors have suggested a function of AChEIs not only in the induction of AChE overproduction and alternative splicing shifts but also a possible role of these drugs in amyloid metabolism beyond their well-known symptomatic effect. Here, we investigate the mechanisms of action of the AChEI donepezil on APP (amyloid precursor protein) metabolism and on the activity/trafficking of the alpha-secretase candidate ADAM 10, in differentiated human neuroblastoma cells (SH-SY5Y). In these cells, the activity of AChE is significantly decreased after 2 h of donepezil treatment. Further, SH-SY5Y cells released significantly more sAPPα into the medium, whereas total APP levels in cell lysates were unchanged. Interestingly, treated cells showed increased ADAM 10 levels in membrane compartments. This effect was prevented by pretreatment with tunicamycin or brefeldin, suggesting that donepezil affects trafficking and/or maturation of ADAM 10; additionally, this pretreatment significantly decreased sAPPα levels. Pre-incubation with atropine decreased release of sAPPα significantly but did not revert ADAM 10 activity to control levels further suggesting that donepezil acts not solely through a purely receptor mediated pathway. These findings indicate that donepezil exerts multiple mechanisms involving processing and trafficking of key proteins involved in AD pathogenesis.

KW - Acetylcholinesterase

KW - ADAM 10

KW - Alzheimer's disease

KW - Donepezil

KW - Neuroblastoma

KW - Trafficking

UR - http://www.scopus.com/inward/record.url?scp=4544239545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544239545&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2004.02680.x

DO - 10.1111/j.1471-4159.2004.02680.x

M3 - Article

C2 - 15341532

AN - SCOPUS:4544239545

VL - 90

SP - 1489

EP - 1499

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 6

ER -